美股新聞 標題聯播 · 近 24 小時 337 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · BIVI近 30 天 12 則 · 第 1 / 1 頁
- New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
- Alliance Entertainment and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
- Join BioVie's Exclusive Live Investor Webinar: Inside the ADDRESS-LC Phase 2 Results
- BioVie Shares Fall 9.7% After Long COVID Trial Misses Statistical Significance in Full Population
- BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
- BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid
- BioVie’s lead therapy candidate shows improvement in key long COVID symptoms
- Dow closes sharply lower as oil surge fuels inflation fears
- BioVie advances Parkinson’s Phase 3 development program with FDA engagement
- BioVie Announces Update to Parkinson’s Phase 3 Development Program
- BioVie completes final patient visit in Phase 2 Long COVID trial
- BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
- First Phosphate and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
- Parkinson's drug developers are betting big on inflammation
- Join Biovie's Exclusive Live Investor Webinar: Inside the SUNRISE-PD Topline Results
- BioVie stock sinks on Phase IIb Parkinson’s trial data
- BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim
- BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease
- BioVie reports positive phase 2 Parkinson's results, eyes pivotal Phase 3 trial
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。